Evidence map›Paper›PMID 40828668›Full record

ArticleVirulence2025

Combination of isobavachalcone and amphotericin B has antifungal effect against

Weidong Qian, Na Liu, Jiaxing Lu, Qiming Liu, Si Chen, Ting Wang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Weidong QianSchool of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an, China.ORCID 0000-0003-4612-4351
Na LiuSchool of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an, China.
Jiaxing LuSchool of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an, China.
Qiming LiuSchool of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an, China.
Si ChenShenzhen University Medical School, Shenzhen University, Shenzhen, China.
Ting WangSchool of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an, China.ORCID 0000-0001-8402-6838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advancements in antifungal therapy, the antifungal armamentarium remains limited compared to antibiotics available for bacterial infections. Developing novel and effective therapeutic strategies is imperative but challenging. One promising approach involves synergizing existing antifungals with complementary agents to enhance efficacy and reduce the required dosages. This study investigates the synergistic effect of isobavachalcone (IBC) and amphotericin B (AmB) against

Indexed as

Amphotericin BAntifungal AgentsChalconesCryptococcosisCryptococcus neoformansFerroptosisAnimalsCaenorhabditis elegansDisease Models, AnimalDrug SynergismGlutathioneMicrobial Sensitivity TestsReactive Oxygen SpeciesAmphotericin BAntifungal AgentsChalconesGlutathioneisobavachalconeReactive Oxygen Speciesamphotericin BCaenorhabditis elegansCryptococcus neoformansferroptosisIsobavachalcone

Identifiers

PMID40828668
PMCPMC12366827

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.